Beximco begins exporting Betapace generic to the US

Generic pharmaceutical product and active pharmaceutical ingredient manufacturer Beximco Pharmaceuticals has commenced the export of sotalol hydrochloride in strengths of 80 mg, 120 mg and 160 mg - a generic version of the cardiovascular drug Betapace - to the US, it announced on Tuesday.

The AIM-traded company said that, following the successful launch of Carvedilol to the US in August last year, it was the second product from Beximco Pharma to be exported to the country.

According to QuintlesIMS data, the market size for sotalol hydrochloride - including all strengths - in the US is $23m.

Beximco said the first consignment was delivered on 29 October, and the product would be distributed through the company's existing partner in the US.

“We are delighted to strengthen our presence in the US with the launch of our second product in this market,” said Beximco managing director Nazmul Hassan.

“With the export of our first product to the US in August 2016, we began a new era for the pharmaceutical industry in Bangladesh that we continue to build with the launch of Sotalol.”

Hassan said Beximco Pharma remained the only Bangladeshi company to export pharmaceutical products to the US, which he called a “validation” of its expertise in offering specialised generic products in a global setting.

“With our growing pipeline for the US, we will focus on increasing our presence in the world's largest pharma market in the coming years.”